Growth Metrics

Gilead Sciences (GILD) EBIT (QoQ) (2009 - 2026)

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Novartis Ag 107,124,802.25 Bn 107,124,802.25 Bn -
2 Eli Lilly 969.00 Bn 963.72 Bn 16.22 Bn
3 Johnson & Johnson 539.46 Bn 517.41 Bn 15.96 Bn
4 AbbVie 376.92 Bn 367.57 Bn 10.78 Bn
5 Merck 285.00 Bn 279.35 Bn 12.09 Bn
6 Amgen 177.58 Bn 165.55 Bn 5.87 Bn
7 Gilead Sciences 163.22 Bn 155.50 Bn 5.52 Bn
8 Pfizer 145.86 Bn 133.09 Bn -1.21 Bn
9 Bristol Myers Squibb 111.90 Bn 101.44 Bn 8.07 Bn
10 Gsk 88.34 Bn 83.66 Bn -

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 30.34%
Dec 31, 2025 -40.37%
Sep 30, 2025 34.48%
Jun 30, 2025 10.59%
Mar 31, 2025 -8.77%
Dec 31, 2024 176.13%
Sep 30, 2024 -66.41%
Jun 30, 2024 161.18%
Mar 31, 2024 -368.11%
Dec 31, 2023 -38.54%
Sep 30, 2023 57.54%
Jun 30, 2023 -2.35%
Mar 31, 2023 -24.79%
Dec 31, 2022 -20.09%
Sep 30, 2022 39.82%
Jun 30, 2022 929.95%
Mar 31, 2022 -79.04%
Dec 31, 2021 -75.53%
Sep 30, 2021 71.06%
Jun 30, 2021 -22.28%
Mar 31, 2021 9.02%
Dec 31, 2020 32.48%
Sep 30, 2020 167.08%
Jun 30, 2020 -224.19%
Mar 31, 2020 119.76%
Dec 31, 2019 174.20%
Sep 30, 2019 -160.62%
Jun 30, 2019 8.63%
Mar 31, 2019 95.54%
Dec 31, 2018 -56.39%
Sep 30, 2018 15.04%
Jun 30, 2018 5.90%
Mar 31, 2018 218.96%
Dec 31, 2017 -82.29%
Sep 30, 2017 -10.39%
Jun 30, 2017 12.93%
Mar 31, 2017 -6.87%
Dec 31, 2016 -8.05%
Sep 30, 2016 -3.06%
Jun 30, 2016 -2.43%
Mar 31, 2016 -17.26%
Dec 31, 2015 0.64%
Sep 30, 2015 -0.55%
Jun 30, 2015 4.56%
Mar 31, 2015 24.04%
Dec 31, 2014 24.43%
Sep 30, 2014 -21.12%
Jun 30, 2014 44.99%
Mar 31, 2014 154.21%
Dec 31, 2013 4.28%
Sep 30, 2013 -0.52%
Jun 30, 2013 12.54%
Mar 31, 2013 -7.37%
Dec 31, 2012 6.02%
Sep 30, 2012 -1.43%
Jun 30, 2012 32.36%
Mar 31, 2012 -7.76%
Dec 31, 2011 -13.57%
Sep 30, 2011 -1.28%
Jun 30, 2011 12.72%
Mar 31, 2011 8.75%
Dec 31, 2010 -15.29%
Sep 30, 2010 -1.37%
Jun 30, 2010 -14.51%
Mar 31, 2010 8.98%
Dec 31, 2009 19.12%
Sep 30, 2009 17.52%
Jun 30, 2009 -5.85%